Trends in the Generic Pharmaceutical Industry and Basic Knowledge of Patents and Patent Strategies
S11113
★Utilizing patents as a means of differentiation for generic pharmaceuticals! ★What is your perspective on the invalidation trials conducted by generic pharmaceutical companies as a business strategy?
Speaker Mr. Ichiro Tasaka, Patent Attorney, Nagasawa Patent Office/Tokyo Marunouchi Law Office Target Audience: Engineers and researchers interested in generic development strategies, patent analysis methods, etc. Venue RYUKA Intellectual Property Hall, 22F Seminar Room [Tokyo, Shinjuku] 3-minute walk from "Shinjuku" Station on JR, Odakyu Odawara Line, Keio Line, and Tokyo Metro Marunouchi Line Date and Time November 21, 2011 (Monday) 13:30-16:30 Capacity: 30 people *Registration will close once full. Please apply early. Participation Fee [Early Bird Discount Price] 19,950 yen per person (including tax and textbook fee) *Limited to Tech-Zone members who apply by November 7. Membership registration is free. *After November 7, the [Regular Price] will be 23,100 yen per person (including tax and textbook fee).
Inquire About This Product
basic information
【Lecture Summary】 The generic pharmaceutical industry is steadily expanding under government promotion policies. Foreign companies, companies from other industries, and new drug companies are successively entering the market, intensifying competition in the generic market, including specialized companies. In this context, the utilization of patents related to generic pharmaceuticals is evolving from a passive approach to proactive business development, as seen in invalidation trials and the acquisition of patents for differentiation of generic drugs. This seminar will focus on these topics.
Price range
P2
Delivery Time
P2
Applications/Examples of results
**Program** 1. Trends in the Generic Pharmaceutical Industry 1-2. Diversification of Generic Pharmaceutical Companies 1-3. Movements in Industry Restructuring 1-4. Steering and Patent Strategies of Generic Pharmaceutical Companies 2. New Drugs and Generic Pharmaceuticals 2-1. New Drugs and Exclusive Rights 2-2. Marketization of Generic Pharmaceuticals 2-3. Notification from the Ministry of Health, Labour and Welfare dated June 5, 2009 3. Approval and Patents of Generic Pharmaceuticals 4. Patent Issues Surrounding Generic Pharmaceuticals 4-1. Basic Patents and Peripheral Patents 4-1-1. Basic Patents 4-1-2. Peripheral Patents 4-2. Patent Term Extension System 4-2-1. Significance of this System 4-2-2. Tokyo High Court Case No. Heisei 20 (Gyo-Ke) 10458, Acetate Leuprolide - Premenopausal Breast Cancer Case 4-3. Invalidity Trials 4-3-1. Countermeasures by Generic Pharmaceutical Companies in Infringement Lawsuits 4-3-2. Filing of Invalidity Trials by Generic Pharmaceutical Companies as a Business Strategy 4-3-3. Invalidity Trials for Patent Term Extension Registrations 5. Patent Strategies of Generic Pharmaceutical Companies 5-1. Management Strategies of Generic Pharmaceutical Companies 5-2. Patent Strategies in the Generic Pharmaceutical Business
Company information
Our company has developed its business from "seminar planning" to various forms such as "lecturer dispatch," "publishing planning," "technical consultant dispatch," "trend research," "business matching," and "business development consulting," in order to support clients in a wide range of fields including chemistry, electronics, automotive, energy, medical devices, food, and building materials. By doing so, we have advanced our company and opened up new markets. AndTech promises to continue listening to our clients' voices, entering the business areas and markets they desire, and to remain a company that is loved by our clients, as we share their challenges, think together, and forge new paths.
![[Service Example] Major Pharmaceutical Company J](https://image.mono.ipros.com/public/product/image/10b/2001524340/IPROS10464393397006182558.png?w=280&h=280)
![[Seminar] The Current Status of Biopharmaceuticals Including Vaccines in Our Country](https://image.mono.ipros.com/public/product/image/3d2/2001181608/IPROS32315136463393769928.png?w=280&h=280)
![[Seminar] Current Status of Stable Supply of Pharmaceuticals and Government Initiatives](https://image.mono.ipros.com/public/product/image/2079072/IPROS8378301222553094990.png?w=280&h=280)
